Reading the tape
NASDAQ: BEAM
Beam Therapeutics Inc.
Healthcare · Biotechnology
Market Cap
$2.95B
52w High
$36.44
52w Low
$15.35
P/E
-36.94
Volume
76.59K
Outstanding Shares
102.75M
Price vs Fundamentals
Why The Stock Is Moving
Fundamentals are supporting the moveModerate confidence
Note: The most recent financial data is over 3 months old. Metrics shown may not reflect the latest reporting period.
1Y Price: 44.65%Revenue (TTM): 120.01%FCF (TTM): -1.08%P/S: 29th pct
What changed
The stock rose 44.65% over the last year. Revenue grew 120.01% over the trailing twelve months. Operating margin moved from -654.25% to -274.57%. Free cash flow declined 1.08% over the trailing twelve months.
What the market seems to be pricing
The stock move broadly lines up with stronger business momentum, and the shares are still only around the 29th percentile of their historical P/S range.
What would invalidate this read
Operating margin is at -274.57%. Revenue grew 120.01% — this thesis depends on that trajectory holding. Despite the price move, free cash flow fell 1.08%, which is worth watching as a leading indicator of future pressure. If revenue growth, margins, or free cash flow roll over while the stock keeps climbing, more of the move would be coming from multiple expansion than business progress.
Company profile
Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States.
CEOJohn Evans
SectorHealthcare
IndustryBiotechnology
Employees393
IPO dateFeb 6, 2020
Valuation
Forward P/E—
EV/EBITDA-91.59
Enterprise value$2.74B
Stock splits
No stock splits recorded for this ticker.
Profitability & growth
Revenue growth279.52%
Gross margin-126.14%▲117.56%vs FY2024
Operating margin-274.57%▲58.03%vs FY2024
ROE-6.46%▲87.42%vs FY2024
Analyst consensus
RatingBuy
Target price$40.83▲42.17%
18
Buy
8
Hold
1
Sell
Analyst ratings tend to be lagging indicators. Use as one signal among many.
Earnings
Full quarter-by-quarter history of actuals vs estimates. Switch into compare mode to inspect one metric year-over-year.
Next report
May 5, 2026
Q2 FY26 · EPS est -$1.03 · Revenue est $10.98M
View